Liraglutide Phase 3 Trial for Obese Women with PCOS Completes Primary Data…

The Phase 3 trial investigating liraglutide in obese women with Polycystic Ovary Syndrome (PCOS) reached its primary completion on March 30, 2025. This milestone indicates that data collection for the study's primary objectives has concluded, moving the trial into the analysis phase.

Background

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterized by hormonal imbalances, metabolic issues, and often obesity. The current study, NCT05965908, is specifically designed to evaluate the effects of liraglutide in infertile women with PCOS who are also obese. The trial's brief summary indicates an aim to compare the hormonal, metabolic, and clinical effects of metformin and liraglutide in this patient population.

Trial design

The study, identified as NCT05965908, is a Phase 3, randomized trial. It enrolled a total of 150 participants, all diagnosed with Polycystic Ovary Syndrome. The interventions being investigated are liraglutide and metformin, with the study comparing their respective impacts on the participants. The trial's overall status is listed as COMPLETED, aligning with the primary completion event.

What this means

The primary completion of this Phase 3 trial marks a significant step towards understanding the potential role of liraglutide in managing Polycystic Ovary Syndrome in obese women. With data collection now complete, researchers will proceed with comprehensive data analysis to evaluate the comparative effects of liraglutide and metformin. This analysis will focus on hormonal, metabolic, and clinical parameters, which are crucial for assessing treatment efficacy in PCOS. The findings are anticipated to provide valuable insights for clinicians and patient advocates, potentially informing future therapeutic strategies for infertile women with PCOS who are also obese.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05965908, titled "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome," was posted on March 30, 2025, on clinicaltrials.gov.